INGN-241. Introgen.
Introgen, under license from Corixa (formerly GenQuest), is developing INGN-241, a gene therapy based on the mda-7 gene in combination with the company's adenoviral delivery system, for the potential treatment of cancer. A phase I trial for the treatment of solid tumors was initiated at the end of November 2000.